Mechanism of Action
TpoR (MPL) Activation
The romiplostim TPO-mimetic peptide binds TpoR (also called MPL, the proto-oncogene myeloproliferative leukemia protein) on megakaryocytes and their progenitors. TpoR is a class I cytokine receptor that homodimerizes upon ligand binding, activating JAK2 and downstream STAT5, MAPK, and PI3K signaling pathways. These pathways drive megakaryocyte proliferation from precursor cells, promote megakaryocyte differentiation and maturation, and ultimately increase thrombopoiesis (platelet release from mature megakaryocytes).
Platelet Production Amplification
In healthy individuals, TPO levels are inversely regulated by platelet and megakaryocyte count (platelets absorb TPO via TpoR). In ITP, despite low platelet counts, TPO levels are only modestly elevated because megakaryocyte mass (which also clears TPO) is relatively preserved or increased. Romiplostim bypasses this regulatory ceiling by using a non-TPO-homologous peptide sequence, providing a strong and consistent TpoR stimulus to drive platelet production above the destruction rate.
Immunological Context
ITP results from autoantibodies against platelet surface antigens (mainly GP IIb/IIIa and GP Ib) leading to FcgammaR-mediated phagocytosis by macrophages, and cytotoxic T-cell-mediated platelet destruction. Romiplostim does not address the autoimmune mechanism directly; rather, it overrides it by sufficiently stimulating platelet production. Interestingly, some romiplostim-treated patients achieve sustained remission after stopping treatment, suggesting possible immunomodulatory effects on the autoimmune B-cell response via TpoR on immune cells.
Research Summary
Chronic ITP (Approved)
Standard of CarePivotal trials showed romiplostim achieved platelet response (>50 x10^9/L) in 88% of splenectomized and 79% of non-splenectomized ITP patients versus 14%/0% placebo. Durable responses occurred in 38-61% vs 0-5% placebo. Long-term open-label extensions show sustained efficacy over years of treatment. Romiplostim is now guideline-recommended as second-line after corticosteroids and IVIg for persistent/chronic ITP.
Aplastic Anemia
ClinicalEltrombopag (oral TPO agonist) and romiplostim are approved or under study for refractory aplastic anemia (AA), which involves TpoR-expressing hematopoietic stem cells. Romiplostim combined with immunosuppression improved trilineage hematologic responses in Phase II studies of severe AA. The mechanism appears to involve stimulation of residual hematopoietic stem cells rather than just megakaryocyte expansion.
Chemotherapy-Induced Thrombocytopenia
ResearchChemotherapy-induced thrombocytopenia (CIT) is a common treatment-limiting toxicity. Romiplostim has been studied to accelerate platelet recovery after myelosuppressive chemotherapy, allowing more consistent dosing. Results have been mixed, benefit in some regimens but concerns about potentially stimulating residual tumor cells expressing TpoR have limited broad adoption. This remains an active research area.
Calculate your Romiplostim dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Chronic ITP | Start 1 mcg/kg SC weekly; increase by 1 mcg/kg weekly if platelet count <50 x10^9/L | Once weekly SC; target platelet 50-200 x10^9/L | SC injection |
| Aplastic anemia (research) | 10 mcg/kg SC weekly + immunosuppression | Weekly x 16-24 weeks | SC injection |
| TpoR biology research | 1-100 nM recombinant in cell culture | Single exposure for megakaryocyte differentiation assay | Cell culture medium |
Maximum dose 10 mcg/kg. Platelet counts >200 x10^9/L: reduce dose by 1 mcg/kg. Counts >400 x10^9/L: withhold and resume at reduced dose. Rebound thrombocytopenia possible on abrupt discontinuation.
Interactions
Safety Profile
Romiplostim is generally well-tolerated. Common adverse effects: headache, fatigue, dizziness, injection site reactions. Bone marrow reticulin formation (an increase in marrow fibers) has been observed in ~10% of biopsies, raising concerns about progression to myelofibrosis, though clinical significance is unclear and mostly reversible on stopping. Rebound thrombocytopenia (platelet drop below baseline) occurs in ~10% upon discontinuation, taper rather than abrupt cessation. Thromboembolic events occur at a rate consistent with elevated platelet counts; target platelet counts should not exceed 400 x10^9/L. Rare transformation to AML/MDS in MDS patients who used romiplostim.
References
- [1]Kuter DJ, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395-403.
- [2]Bussel JB, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006.
- [3]Faulkner L, et al. Eltrombopag and romiplostim in aplastic anemia. Br J Haematol. 2018.